MarketCapExport financials
Veeva Systems (VEEV)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Veeva Systems Income Statement 2026-2011 | VEEV
Brief overview of profit and loss at Veeva Systems
The figures are compared over a five-year interval. According to figures from Veeva Systems, revenue changed from $1.5 billion to $3.2 billion over five years. The total change was +118.1%, with a CAGR of approximately 16.9%. The trajectory reflects meaningful expansion of the business.
Gross profit changed from $1.1 billion to $2.4 billion (+128.5%). Cost of revenue developed more favorably than sales, supporting gross profitability. At the margin level, the figure shifted from 72.1% to 75.5%. A wider margin shows that the economics of the core business improved.
EBITDA was $387 million at the beginning and $930 million at the end of the period (+140.5%). The operating result outpaced sales and points to improving efficiency. Comparing the endpoints gives EBITDA margins of 26.4% and 29.1%. The increased EBITDA share is a positive sign.
Net income changed from $380 million to $909 million (+139.2%). Net profit ended the five years at a local peak.
The five-year change in capitalization reached −21.7%: from $38.5 billion to $30.1 billion. Capitalization lags the underlying business improvement.
Financial takeaway
The results present an uneven picture without one dominant signal. The strongest signals are a stronger gross margin, a larger revenue base and higher operating efficiency. The overall view is constrained by lower investor confidence. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Veeva Systems
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
30.1 B | 29.8 B | 36.8 B | 27.6 B | 27.2 B | 38.5 B | 21 B | 17.3 B | 10.4 B | 5.97 B | 3.31 B | 3.96 B | 1.83 B | - | - | - |
Shares |
164 M | 162 M | 161 M | 155 M | 153 M | 151 M | 148 M | 144 M | 140 M | 136 M | 132 M | 128 M | 51.7 M | - | - | - |
Historical Prices |
184 | 184 | 229 | 178 | 178 | 255 | 272 | 141 | 89.3 | 55.3 | 40.7 | 28.9 | 26.4 | 32.1 | - | - |
Net Income |
909 M | 714 M | 526 M | 488 M | 427 M | 380 M | 301 M | 230 M | 142 M | 68.8 M | 54.5 M | 40.4 M | 23.6 M | 18.8 M | 4.23 M | 3.91 M |
Revenue |
3.2 B | 2.75 B | 2.36 B | 2.16 B | 1.85 B | 1.47 B | 1.1 B | 862 M | 686 M | 544 M | 409 M | 313 M | 210 M | 130 M | 61.3 M | 29.1 M |
Cost of Revenue |
782 M | 700 M | 677 M | 609 M | 504 M | 409 M | 303 M | 245 M | 211 M | 174 M | 142 M | 116 M | 82.6 M | 57 M | 29.1 M | - |
Gross Profit |
2.41 B | 2.05 B | 1.69 B | 1.55 B | 1.35 B | 1.06 B | 801 M | 617 M | 474 M | 370 M | 267 M | 198 M | 128 M | 72.5 M | 32.2 M | 16.8 M |
Operating Income |
916 M | 691 M | 429 M | 459 M | 505 M | 378 M | 286 M | 223 M | 158 M | 121 M | 78.6 M | 70 M | 39.3 M | 30 M | 6.64 M | - |
Interest Expense |
278 M | 228 M | 159 M | 50 M | 6.82 M | 16.2 M | 27.5 M | 15.8 M | 7.84 M | 1.67 M | 28 K | -2.78 M | -804 K | -940 K | 15 K | - |
EBITDA |
930 M | 710 M | 435 M | 465 M | 512 M | 387 M | 306 M | 237 M | 165 M | 122 M | 87.1 M | 73.9 M | 41.7 M | 30.8 M | 7.04 M | 5.31 M |
Operating Expenses |
1.5 B | 1.36 B | 1.26 B | 1.09 B | 842 M | 678 M | 514 M | 394 M | 323 M | 262 M | 188 M | 128 M | 88.2 M | 42.5 M | 25.6 M | 11.7 M |
General and Administrative Expenses |
301 M | 266 M | 247 M | 218 M | 172 M | 149 M | 114 M | 86.4 M | 60.4 M | 48.8 M | 41.5 M | 30.2 M | 20.4 M | 8.37 M | 5.54 M | 2.51 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Veeva Systems
| 2027-Q2 | 2027-Q1 | 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
163 M | 163 M | - | 164 M | 163 M | 163 M | - | 164 M | 163 M | 163 M | - | 162 M | 162 M | 161 M | - | 161 M | 160 M | 160 M | - | 155 M | 155 M | 155 M | - | 154 M | 153 M | 152 M | - | 151 M | 150 M | 150 M | - | 148 M | 148 M | 147 M | - | 145 M | 144 M | 143 M | - | 141 M | 140 M | 137 M | - | 136 M | 135 M | 134 M | 130 M | 132 M | 132 M | 131 M | 123 M | 129 M | 127 M | 124 M | 24.8 M | 35.8 M | 24.4 M | 21.6 M | - | 20.7 M | - | - | - | - | - | - |
Net Income |
200 M | 261 M | - | 236 M | 200 M | 228 M | - | 236 M | 200 M | 228 M | - | 186 M | 171 M | 162 M | - | 135 M | 112 M | 132 M | - | 108 M | 90.6 M | 100 M | 103 M | 106 M | 109 M | 116 M | 66.2 M | 97 M | 93.6 M | 86.6 M | 71.2 M | 82.2 M | 79.2 M | 73.4 M | 40.7 M | 64.1 M | 50.3 M | 44.3 M | 21.7 M | 34.9 M | 38.6 M | 37 M | 17.6 M | 21.6 M | 13 M | 12.5 M | 13.3 M | 10.5 M | 13.4 M | 13 M | 6.25 M | 10.3 M | 9.58 M | 7.22 M | 5.68 M | 6.52 M | 6 M | 4.84 M | - | 5.75 M | 4.25 M | 3.1 M | - | - | - | - |
Revenue |
789 M | 883 M | - | 811 M | 789 M | 759 M | - | 811 M | 789 M | 759 M | - | 699 M | 676 M | 650 M | - | 617 M | 590 M | 526 M | - | 552 M | 534 M | 505 M | 397 M | 476 M | 456 M | 434 M | 312 M | 378 M | 354 M | 337 M | 232 M | 281 M | 267 M | 245 M | 186 M | 225 M | 210 M | 196 M | 150 M | 177 M | 168 M | 160 M | 114 M | 143 M | 131 M | 120 M | 87 M | 107 M | 98.1 M | 89.9 M | 62.8 M | 83.8 M | 75.7 M | 66.7 M | 39.8 M | 55 M | 49.6 M | 42.8 M | - | 35.8 M | 29.5 M | 24.5 M | - | - | - | - |
Cost of Revenue |
195 M | 221 M | - | 199 M | 195 M | 174 M | - | 199 M | 195 M | 174 M | - | 174 M | 170 M | 174 M | - | 168 M | 169 M | 167 M | - | 154 M | 152 M | 140 M | - | 130 M | 122 M | 116 M | - | 103 M | 97.2 M | 94.9 M | - | 73.3 M | 70.2 M | 65.5 M | - | 61.4 M | 59.2 M | 60.2 M | - | 53.2 M | 50.4 M | 48.9 M | - | 43.9 M | 42.2 M | 41.1 M | 31.2 M | 37 M | 33.5 M | 32 M | 24.4 M | 30.4 M | 28.1 M | 26 M | 16.8 M | 21.4 M | 19.1 M | 17.7 M | - | 15.9 M | 13 M | 11.3 M | - | - | - | - |
Gross Profit |
594 M | 662 M | - | 612 M | 594 M | 585 M | - | 612 M | 594 M | 585 M | - | 525 M | 506 M | 476 M | - | 449 M | 421 M | 360 M | - | 398 M | 383 M | 366 M | 283 M | 347 M | 333 M | 317 M | 217 M | 275 M | 256 M | 242 M | 168 M | 208 M | 197 M | 179 M | 127 M | 163 M | 150 M | 135 M | 104 M | 124 M | 117 M | 111 M | 74.5 M | 98.9 M | 89.2 M | 78.7 M | 55.9 M | 69.9 M | 64.6 M | 57.9 M | 38.4 M | 53.4 M | 47.5 M | 40.8 M | 23 M | 33.6 M | 30.4 M | 25.1 M | - | 19.9 M | 16.4 M | 13.2 M | - | - | - | - |
Operating Income |
196 M | 273 M | - | 241 M | 196 M | 234 M | - | 241 M | 196 M | 234 M | - | 181 M | 166 M | 155 M | - | 128 M | 104 M | 61.5 M | - | 121 M | 101 M | 128 M | 98.8 M | 133 M | 125 M | 128 M | 60.4 M | 101 M | 90.1 M | 87.6 M | 63 M | 80.8 M | 73.9 M | 71.2 M | 38.5 M | 63.1 M | 52.8 M | 44 M | 32.5 M | 42.5 M | 38.1 M | 38.9 M | 15.2 M | 33.8 M | 23.8 M | 17.8 M | 20.7 M | 20.1 M | 22.4 M | 20.9 M | 11.3 M | 19.9 M | 16.8 M | 12.6 M | 9.36 M | 9.98 M | 9.84 M | 8.17 M | - | 8.78 M | 7.12 M | 4.76 M | - | - | - | - |
Interest Expense |
69.5 M | 74.4 M | - | 71.9 M | 69.5 M | 65.1 M | - | 71.9 M | 69.5 M | 65.1 M | - | 60.9 M | 58.6 M | 51.7 M | - | 42.2 M | 38.8 M | 30.2 M | - | 12.5 M | 8.4 M | 2.71 M | - | 824 K | 1.67 M | 4.56 M | - | 3.46 M | 2.88 M | 3.41 M | - | 9.14 M | 7.33 M | 6.16 M | - | 4.61 M | 3.34 M | 2.14 M | - | 1.36 M | 2.86 M | 591 K | - | 525 K | -1.36 M | 2.75 M | -1.66 M | 110 K | -445 K | 763 K | -365 K | -989 K | -101 K | -30 K | -603 K | 125 K | -65 K | -499 K | - | 74 K | -421 K | 10 K | - | - | - | - |
EBITDA |
200 M | 276 M | - | 245 M | 200 M | 238 M | - | 245 M | 200 M | 238 M | - | 186 M | 171 M | 160 M | - | 133 M | 105 M | 62.5 M | - | 122 M | 103 M | 130 M | 98.8 M | 135 M | 127 M | 130 M | 60.4 M | 103 M | 92.1 M | 89.6 M | 63 M | 86.4 M | 79.4 M | 76.6 M | 38.5 M | 66.5 M | 56.3 M | 47.6 M | 32.5 M | 46.1 M | 41.6 M | 42.3 M | 15.2 M | 37.3 M | 27.3 M | 21.2 M | 20.7 M | 22.6 M | 23.7 M | 21.9 M | 11.3 M | 21 M | 17.8 M | 13.5 M | 9.36 M | 10.8 M | 10.3 M | 8.44 M | - | 8.96 M | 7.12 M | 4.76 M | - | - | - | - |
Operating Expenses |
398 M | 389 M | - | 371 M | 398 M | 351 M | - | 371 M | 398 M | 351 M | - | 343 M | 339 M | 321 M | - | 320 M | 317 M | 298 M | - | 277 M | 281 M | 238 M | - | 214 M | 209 M | 189 M | - | 173 M | 166 M | 155 M | - | 127 M | 123 M | 108 M | - | 100 M | 97.6 M | 91.4 M | - | 81.3 M | 79.3 M | 72 M | - | 65 M | 65.3 M | 60.9 M | 35.2 M | 49.8 M | 42.3 M | 37 M | 27.1 M | 33.5 M | 30.7 M | 28.2 M | 13.7 M | 23.6 M | 20.6 M | 16.9 M | - | 11.2 M | 9.28 M | 8.4 M | - | - | - | - |
General and Administrative Expenses |
95.8 M | 69.5 M | - | 68.5 M | 95.8 M | 68.8 M | - | 68.5 M | 95.8 M | 68.8 M | - | 72.4 M | 61.4 M | 61.3 M | - | 62.3 M | 62.9 M | 62.7 M | - | 52.9 M | 57.8 M | 48.3 M | - | 42.8 M | 42.2 M | 41.2 M | - | 35.2 M | 37.2 M | 36.7 M | - | 28.7 M | 25.9 M | 23.5 M | - | 22.6 M | 20.5 M | 19.9 M | - | 15.4 M | 14.6 M | 13.6 M | - | 11.6 M | 12.9 M | 12.1 M | 8.1 M | 11.8 M | 8.97 M | 8.56 M | 6.51 M | 8.58 M | 7.15 M | 6.41 M | 2.79 M | 5.55 M | 4.63 M | 3.72 M | - | 2.24 M | 1.81 M | 1.54 M | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Veeva Systems (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Phreesia
PHR
|
$ 13.15 | 1.94 % | $ 786 M |  USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.34 | -1.37 % | $ 173 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
10x Genomics
TXG
|
$ 62.88 | -3.34 % | $ 7.84 B | USA |
 |
SCWorx Corp.
WORX
|
$ 1.31 | -5.76 % | $ 9.53 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.94 | -5.99 % | $ 3.21 M |  China |
 |
HealthStream
HSTM
|
$ 28.69 | -0.14 % | $ 861 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
So-Young International
SY
|
$ 2.0 | 0.5 % | $ 156 M | China |
 |
American Well Corporation
AMWL
|
$ 12.0 | -3.73 % | $ 193 M | USA |
 |
Evolent Health
EVH
|
$ 4.79 | 1.7 % | $ 547 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.54 | -3.01 % | $ 1.26 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.46 | -3.31 % | $ 102 M | USA |
 |
HealthEquity
HQY
|
$ 103.68 | 1.53 % | $ 8.93 B | USA |
 |
Omnicell
OMCL
|
$ 35.87 | -3.96 % | $ 1.65 B | USA |
 |
Progyny
PGNY
|
$ 36.44 | 1.35 % | $ 3.11 B | USA |
 |
Schrödinger
SDGR
|
$ 32.42 | -2.89 % | $ 2.38 B | USA |
 |
Teladoc Health
TDOC
|
$ 8.96 | -0.28 % | $ 1.58 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |